Rankings
▼
Calendar
NVAX Q4 2025 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena
NVAX
Novavax, Inc.
$2B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$147M
+66.6% YoY
Gross Profit
$122M
82.9% margin
Operating Income
$21M
14.3% margin
Net Income
$18M
11.9% margin
EPS (Diluted)
$0.11
QoQ Revenue Growth
+108.9%
Cash Flow
Operating Cash Flow
-$39M
Free Cash Flow
-$42M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$1.2B
Total Liabilities
$1.3B
Stockholders' Equity
-$128M
Cash & Equivalents
$241M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$147M
$88M
+66.6%
Gross Profit
$122M
$52M
+136.1%
Operating Income
$21M
-$131M
+116.0%
Net Income
$18M
-$81M
+121.6%
Revenue Segments
Product
$661M
94%
Supply Sales
$20M
3%
Nuvaxovid Sales
$20M
3%
Geographic Segments
UNITED STATES
$111M
76%
Rest of the World
$33M
22%
Europe
$3M
2%
← FY 2025
All Quarters